HCPCS Level II code Q5117 designates a 10 mg unit of trastuzumab-anns, the biosimilar sold as Kanjinti, used for parenteral administration in oncology. This drug-level code is essential for accurate drug billing, inventory tracking, and payment for biologic therapies nationally, especially as biosimilars play an increasing role in cost-containment and access to monoclonal antibody treatments. Key payers in typical coverage analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what Q5117 represents clinically and operationally, followed by benchmarking context and payer coverage considerations. The publication covers pricing and reimbursement benchmarks where available, typical sites of service for administration, and policy updates that affect biosimilar billing and coding. Clinical context on trastuzumab biosimilars, including common use cases and implications for infusion services, is also provided. Data not available in the input will be noted where applicable.